UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
SEEL holding history
Seelos Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
SEEL overviewAll 13F holders of SEELFull Q2 2026 holdings
- Shares (Q4 2024)
- 0
- Sold out in Q4 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 15
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2024 | 0 | $0 | 0.0% | −8,477−100.0% | Sold out | Holders |
| Q3 2024 | 8,477 | $31.8K | <0.1% | +8,474+271,164.0% | AddedConverted for a 1-for-16 split | Holders |
| Q2 2024 | 50 | $30 | <0.1% | −10,116−99.5% | Reduced | Holders |
| Q1 2024 | 10,166 | $6.01K | <0.1% | +9,759+2,397.8% | Added | Holders |
| Q4 2023 | 407 | $565 | <0.1% | +333+448.5% | AddedConverted for a 1-for-30 split | Holders |
| Q3 2023 | 2,226 | $410 | <0.1% | −72−3.1% | Reduced | Holders |
| Q2 2023 | 2,298 | $2.75K | <0.1% | +72+3.2% | Added | Holders |
| Q1 2023 | 2,226 | $1.54K | <0.1% | −7,517−77.2% | Reduced | Holders |
| Q4 2022 | 9,743 | $6.63K | <0.1% | −13,842−58.7% | Reduced | Holders |
| Q3 2022 | 23,585 | $24.0K | <0.1% | +21,359+959.5% | Added | Holders |
| Q2 2022 | 2,226 | $2.00K | <0.1% | −1,477−39.9% | Reduced | Holders |
| Q1 2022 | 3,703 | $3.00K | <0.1% | −39,837−91.5% | Reduced | Holders |
| Q4 2021 | 43,540 | $70.0K | <0.1% | +40,501+1,332.7% | Added | Holders |
| Q3 2021 | 3,039 | $7.00K | <0.1% | +3,000+7,692.3% | Added | Holders |
| Q2 2021 | 39 | $0 | 0.0% | −8,588−99.5% | Reduced | Holders |
| Q1 2021 | 8,627 | $43.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.